• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amedisys has earned the 2023 SHPBest™ Patient Satisfaction Awards

    9/25/24 7:30:00 AM ET
    $AMED
    Medical/Nursing Services
    Health Care
    Get the next $AMED alert in real time by email

    BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, has 92 home health and hospice care centers recognized by Strategic Healthcare Programs (SHP) for achieving the highest overall HHCAHPS patient satisfaction or CAHPS Hospice caregiver satisfaction scores of all eligible SHP clients in 2023. This includes 14 care centers awarded Premier Performer, ranking in the top 5%, and 78 care centers awarded Superior Performer, ranking in the top 20%. Thirteen care centers achieved an award in each of the last 5 years of the SHPBest program.

    "Nothing we do is possible without our incredible caregivers delivering outstanding care in the home each and every day," stated Scott Ginn, Chief Operating Officer and Chief Financial Officer, Amedisys. "Thanks to our dedicated family of caregivers, Amedisys is truly achieving clinical distinction."

    The annual SHPBest™ award program was created to acknowledge home health and hospice agencies that consistently provide high quality service to their patients and caregivers of patients receiving hospice care. For home health, the 2023 award recipients were determined by reviewing and ranking the overall satisfaction score for more than 3,200 home health providers. For hospice, the 2023 award recipients were determined by reviewing and ranking the overall CAHPS Hospice survey satisfaction score for more than 1,750 hospice providers.

    With the largest HHCAHPS and CAHPS benchmarks in the nation, SHP is in a unique position to identify and recognize organizations that have made patient, family and caregiver satisfaction a priority and have been rewarded for their efforts with high marks on the HHCAHPS and CAHPS Hospice survey.

    "SHP is proud to partner with so many organizations that put a high value on providing quality patient care and we are honored to recognize the hard work and dedication of our top-performing customers with the annual SHPBest awards. These organizations deserve to be celebrated for their commitment to achieving new levels of excellence each and every year," said Kevin Vogel, President of SHP.

    Read more about the SHPBest awards program, including methodology and award recipient lists at https://www.shpdata.com/home-health/shpbest-hhcahps and https://www.shpdata.com/hospice/shpbest-cahps-hospice/.

    About Amedisys:

    Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is inpatient hospital, palliative, and skilled nursing facility ("SNF") care in their homes; home-based recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. Nearly 3,000 hospitals and more than 110,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 19,000 employees in 521 care centers in 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of nearly 470,000 patients in need every year, performing more than 10.6 million visits annually. For more information about the Company, please visit: www.amedisys.com.



    About Strategic Healthcare Programs (SHP)

    Strategic Healthcare Programs (SHP) is a leader in data analytics and benchmarking that drive daily clinical and operational decisions. Our solutions bring real-time data to post-acute providers, hospitals, and ACOs to better coordinate quality care and improve patient outcomes. Since 1996, SHP has helped more than 7,000 organizations nationwide raise the bar for healthcare performance.

    Contact:
    Nick Muscato Kendra Kimmons
    Amedisys, Inc. Amedisys, Inc.
    Chief Strategy Officer Media Relations
    615.928.5452 225.299.3720
    [email protected] [email protected]


    Primary Logo

    Get the next $AMED alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMED

    DatePrice TargetRatingAnalyst
    7/29/2024$101.00Buy → Hold
    Deutsche Bank
    7/1/2024Outperform → Mkt Perform
    William Blair
    6/7/2023$97.00Buy → Hold
    Truist
    4/21/2023$87.00Neutral
    Cantor Fitzgerald
    3/13/2023$93.00Equal Weight
    Barclays
    10/27/2022Outperform → Mkt Perform
    Raymond James
    8/2/2022$145.00 → $95.00Neutral → Sell
    UBS
    6/29/2022$128.00Hold
    Stifel
    More analyst ratings

    $AMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Griffin Jennifer G returned 20,173 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - AMEDISYS INC (0000896262) (Issuer)

    8/14/25 4:02:31 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Director Capps Vickie L returned 9,818 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - AMEDISYS INC (0000896262) (Issuer)

    8/14/25 4:02:38 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Director Kline Teresa L. returned 9,818 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - AMEDISYS INC (0000896262) (Issuer)

    8/14/25 4:02:47 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    SEC Filings

    View All

    SEC Form S-8 POS filed by Amedisys Inc

    S-8 POS - AMEDISYS INC (0000896262) (Filer)

    8/14/25 4:46:39 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    SEC Form S-8 POS filed by Amedisys Inc

    S-8 POS - AMEDISYS INC (0000896262) (Filer)

    8/14/25 4:46:26 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    SEC Form S-8 POS filed by Amedisys Inc

    S-8 POS - AMEDISYS INC (0000896262) (Filer)

    8/14/25 4:46:15 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Amedisys downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Amedisys from Buy to Hold and set a new price target of $101.00

    7/29/24 7:29:37 AM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Amedisys downgraded by William Blair

    William Blair downgraded Amedisys from Outperform to Mkt Perform

    7/1/24 7:29:43 AM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Amedisys downgraded by Truist with a new price target

    Truist downgraded Amedisys from Buy to Hold and set a new price target of $97.00

    6/7/23 9:03:46 AM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Twilio Set to Join S&P MidCap 400

    NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE:TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE:UNH) acquired Amedisys in a deal completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector August 19, 2025 S&P MidCap 400 Addition Twilio TWLO Information Technology August 19, 2025 S&P MidCap 400 Deletion Amedisys AMED Health Care For more information about S&P Dow Jones Indices, please visit www.spdji

    8/14/25 6:08:00 PM ET
    $AMED
    $SPGI
    $TWLO
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    Amedisys Reports Second Quarter 2025 Financial Results

    BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2025. Three-Month Periods Ended June 30, 2025 and 2024 Net service revenue increased $30.7 million to $621.9 million compared to $591.2 million in 2024.Net income attributable to Amedisys, Inc. of $28.1 million, which is inclusive of merger-related expenses totaling $26.3 million ($26.1 million, net of tax), compared to net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) in 2024.Net income attributable to Amed

    7/29/25 4:45:52 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Amedisys Reports First Quarter 2025 Financial Results

    BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March 31, 2025 and 2024 Net service revenue increased $23.4 million to $594.8 million compared to $571.4 million in 2024.Net income attributable to Amedisys, Inc. of $61.0 million, which is inclusive of merger-related expenses totaling $16.8 million ($16.6 million, net of tax) and a $48.1 million gain on an equity method investment ($35.6 million, net of tax), compared to net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 milli

    4/23/25 4:45:43 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

    SC 13G/A - AMEDISYS INC (0000896262) (Subject)

    2/13/24 4:58:48 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

    SC 13G/A - AMEDISYS INC (0000896262) (Subject)

    2/12/24 5:24:28 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

    SC 13G/A - AMEDISYS INC (0000896262) (Subject)

    2/8/24 10:18:47 AM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    Financials

    Live finance-specific insights

    View All

    AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE

    BATON ROUGE, La., May 3, 2023 /PRNewswire/ -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2023. Three-Month Periods Ended March 31, 2023 and 2022 Net service revenue increased $11.1 million to $556.4 million compared to $545.3 million in 2022.Net income attributable to Amedisys, Inc. of $25.2 million compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted share of $0.77 compared to $0.97 in 2022.Adjusted Quarterly Results* Adjusted EBITDA of $57.8 million compared to $66.3 million

    5/3/23 4:31:00 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care

    All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive Capabilities Across Alternate Site Care Spectrum Position Combined Company to Move Deeper into Value-Based Care Highly Attractive Combined Financial Profile Which Generated $6.2 Billion in Revenues and $622 Million in Adjusted EBITDA on a Combined Basis for Full Year 2022 Creates Stockholder Value Including Through Anticipated Annual Run-Rate Revenue and Cost Synergies of Approximately $75 Million by Year Three Following Clo

    5/3/23 4:30:00 PM ET
    $AMED
    $OPCH
    Medical/Nursing Services
    Health Care

    Amedisys Announces First Quarter 2023 Earnings Release and Conference Call Date

    BATON ROUGE, La., April 20, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care, will report results for the first quarter ended March 31, 2023, after the market closes on May 3, 2023. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2023. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (888) 437-3179 (toll-free) or (862) 298-0702 (toll). A replay of the call will be available through June 4, 2023, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13737736. To access a live webcast of th

    4/20/23 8:00:00 AM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    Leadership Updates

    Live Leadership Updates

    View All

    Twilio Set to Join S&P MidCap 400

    NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE:TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE:UNH) acquired Amedisys in a deal completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector August 19, 2025 S&P MidCap 400 Addition Twilio TWLO Information Technology August 19, 2025 S&P MidCap 400 Deletion Amedisys AMED Health Care For more information about S&P Dow Jones Indices, please visit www.spdji

    8/14/25 6:08:00 PM ET
    $AMED
    $SPGI
    $TWLO
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    Amedisys Reports Second Quarter 2024 Financial Results

    BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.Net income attributa

    7/24/24 4:30:52 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Amedisys Reports First Quarter 2024 Financial Results

    BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023.Net income attributable to Amedisys, Inc. per diluted share o

    4/24/24 4:45:46 PM ET
    $AMED
    Medical/Nursing Services
    Health Care